In 1976 Ebola revealed itself to the world, marking the beginning of a series of localized
outbreaks. However, it was the Ebola outbreak that began in 2013 that incited fear and …

Neutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral
infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have …

The endemic nature of the Ebola virus disease in Africa underscores the need for
prophylactic and therapeutic drugs that are affordable and easy to administer. Through a …

Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of
remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we …

Advances in antibody technologies have resulted in the development of potent antibody‐
based therapeutics with proven clinical efficacy against infectious diseases. Several …

We construct and analyse nonstandard finite difference (NSFD) schemes for two epidemic
optimal control problems. Firstly, we consider the well-known MSEIR system that can be …

The Ebola filovirus (EBOV) poses a serious threat to global health and national security.
Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic …

Objectives: Identify the etiology and pathogenesis of Ebola-related medical conditions and
emergencies. Identify risk factors for Ebola virus disease. Select appropriate therapies for …

Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are
highly selective, well tolerated, and have long in vivo half-life as well as the capacity to …

Background Ebola virus disease (EVD) survivors experience ocular sequelae including
retinal lesions, cataracts, and vision loss. While monoclonal antibodies targeting the Ebola …